Find out how Genovac is delivering 10-fold more lead candidates against difficult targets.
Download FileDiscover how you can maximize hit recovery and rapidly down-select blocking antibodies from plasma B cells in a single day.
Download this application note to learn about how the Opto™ Plasma B Discovery workflow increases hit recovery for difficult membrane-bound targets and provides access to greater sequence diversity when compared to traditional hybridoma methods.
Learn how we enable lead candidate down-selection in 1 day by performing functional characterization during primary screening. Case studies highlight how our customers are dramatically accelerating development of next-generation antibody therapeutics.